Non-ergot Dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9nM for D3, D2S, D2L and D4 receptors respectively). Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Shows good solubility in aqueous media (100mM water and 100mM DMSO). Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinsons disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). Synonyms: Pramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-N-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride CAS Number: 104632-25-9 Molecular Formula: C10H17N3S2HCl Solubility: H2O Primary Target: D3 Primary Target Ki: 0.5nM Storage and Stability: May be stored at 4C. For long-term storage, aliquot and store at 4C. Do not freeze. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
Reinheit:
99% (HPLC)
Formulierung:
Supplied as a white solid.
CAS Nummer:
[104632-25-9]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
